Identifying Patients with EGFR-Mutated Oligometastatic NSCLC Suitable for Third-Generation EGFR-TKI Combined with Thoracic Radiotherapy Using Nomograms Based on CT Radiomic and Clinicopathological Factors.

Abstract excerpt

RATIONALE AND OBJECTIVES: It remains uncertain whether all patients with oligometastatic non-small cell lung cancer (NSCLC) benefit from the combination of third-generation EGFR-TKIs and TRT. This study aimed to identify which patients are most likely to benefit from combined third-generation EGFR-TKI and TRT, and which patients may safely omit TRT, thereby guiding clinical decision-making and optimizing...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Carcinoma, Non-Small-Cell Lung